Bone Marrow Transplantation
Bone Marrow Transplants (BMT) are a critical treatment modality for various pediatric malignancies and some non-malignant conditions. In pediatric oncology, BMT is particularly applicable in cases of high-risk or relapsed leukemia, relapsed lymphomas, some solid tumors like neuroblastoma, and certain brain tumors. BMT can be categorized into autologous transplants, in which the patient’s own stem cells are used, and allogeneic transplants, in which stem cells from a genetically compatible donor are used.
Process of Bone Marrow Transplantation
The BMT process begins with selecting a suitable donor for allogeneic transplants, which can be a sibling, a family member, or an unrelated donor from a national or international registry. In autologous transplants, stem cells are harvested from the patient before chemotherapy or radiation therapy.
Once a donor is identified, the patient undergoes a conditioning regimen, which involves high-dose chemotherapy and sometimes radiation therapy to eliminate the cancer cells and suppress the immune system to prevent graft rejection. The conditioning regimen’s intensity can vary depending on the type of transplant and the underlying disease.
Following conditioning, the stem cells are infused into the patient’s bloodstream, similar to a blood transfusion. These cells then migrate to the bone marrow, where they begin to produce healthy blood cells, a process known as engraftment (Kenyon & Babic, 2023). The period following the infusion and before engraftment is particularly critical, as the patient has a weakened immune system and is susceptible to infections.
After engraftment, patients are closely monitored for complications, including graft-versus-host disease (GVHD) in allogeneic transplants, where the donor’s immune cells attack the recipient’s tissues. Immunosuppressive medications are often used to reduce the risk of GVHD.
Total Body Irradiation (TBI)
Total Body Irradiation (TBI) is a form of radiation therapy used as part of the conditioning regimen before a BMT. TBI involves exposing the entire body to radiation to destroy cancer cells, eradicate the patient’s bone marrow, and suppress the immune system to reduce the risk of graft rejection.
Process of Total Body Irradiation
The TBI process is meticulously planned and delivered by a team of radiation oncologists, medical physicists, and radiation therapists. Patients are placed in a specific position to ensure uniform radiation exposure of the entire body. The radiation dose is administered over several sessions, typically twice a day for several days. Lead shields may be used to protect vital organs, such as the lungs and kidneys, from excessive lead exposure.
TBI serves multiple purposes, such as eliminating residual cancer cells, creating space in the bone marrow for transplanted stem cells, and weakening the immune response to reduce the risk of graft rejection.
Role of TBI in BMT
TBI plays a crucial role in the success of BMT by increasing the chances of complete eradication of the malignancy and creating an optimal environment for the donor stem cells to engraft. It is a powerful tool, especially in cases of leukemia, where it can reach cancer cells that may have spread throughout the body.
Success and Survival Rates
The success of BMT and pediatric patients’ survival rates depend on various factors, including the type of malignancy, the stage of the disease at the time of transplant, the patient’s overall health, the type of transplant (autologous vs. allogeneic), and the presence of GVHD or other complications.
In general, BMT has significantly improved survival rates for children with high-risk or relapsed hematologic malignancies. For instance, survival rates for pediatric acute lymphoblastic leukemia (ALL) have improved considerably with the use of BMT in appropriate cases. However, the outcomes vary, and long-term survival can range from less than 50% to over 90%, depending on the specific circumstances.
Autologous transplants tend to have lower rates of complications like GVHD. Still, they may not be as effective against certain types of cancer because they lack the graft-versus-tumor effect that can occur with allogeneic transplants. Allogeneic transplants carry a higher risk of complications but can sometimes offer a better chance at curing the underlying malignancy due to the immune response from the donor cells.
Reference
Kenyon, M., & Babic, A. (2023). The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT. Springer Nature.